Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahrukh S Rizvi

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Applied Laboratory Medicine|February 27, 2021
Biomarkers for Early Detection of Acute Kidney InjuryMahrukh S Rizvi, Kianoush B Kashani
Critical Care Explorations|March 31, 2021
New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine CascadeMahrukh S Rizvi, Alice Gallo De Moraes
Critical Care Medicine|December 14, 2019
The authors replyMahrukh S Rizvi, Andrea M Nei, Ognjen Gajic, et al.
Critical Care Medicine|September 17, 2019
The authors replyMahrukh S Rizvi, Ognjen Gajic, Andrea M Nei, et al.
BMJ Case Reports|June 1, 2018
Severe <i>Babesia microti</i> infection presenting as multiorgan failure in an immunocompetent hostJuan G Ripoll, Mahrukh S Rizvi, Rebecca L King, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 7, 2016
What Are We Doing? A Survey of United States Nephrology Fellowship Program DirectorsScott E Liebman, Catherine A Moore, Rebeca D Monk, et al.
Critical Care Medicine|May 21, 2019
Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective StudyMahrukh S Rizvi, Andrea M Nei, Ognjen Gajic, et al.
Critical Care Medicine|April 4, 2018
Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case SeriesMahrukh S Rizvi, Vrinda Trivedi, Faria Nasim, et al.
Critical Care Explorations|May 12, 2021
Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical TrialAmos Lal, Vrinda Trivedi, Mahrukh S Rizvi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Applied Laboratory Medicine|February 27, 2021
Biomarkers for Early Detection of Acute Kidney InjuryMahrukh S Rizvi, Kianoush B Kashani
Critical Care Explorations|March 31, 2021
New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine CascadeMahrukh S Rizvi, Alice Gallo De Moraes
Critical Care Medicine|December 14, 2019
The authors replyMahrukh S Rizvi, Andrea M Nei, Ognjen Gajic, et al.
Critical Care Medicine|September 17, 2019
The authors replyMahrukh S Rizvi, Ognjen Gajic, Andrea M Nei, et al.
BMJ Case Reports|June 1, 2018
Severe <i>Babesia microti</i> infection presenting as multiorgan failure in an immunocompetent hostJuan G Ripoll, Mahrukh S Rizvi, Rebecca L King, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 7, 2016
What Are We Doing? A Survey of United States Nephrology Fellowship Program DirectorsScott E Liebman, Catherine A Moore, Rebeca D Monk, et al.
Critical Care Medicine|May 21, 2019
Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective StudyMahrukh S Rizvi, Andrea M Nei, Ognjen Gajic, et al.
Critical Care Medicine|April 4, 2018
Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case SeriesMahrukh S Rizvi, Vrinda Trivedi, Faria Nasim, et al.
Critical Care Explorations|May 12, 2021
Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical TrialAmos Lal, Vrinda Trivedi, Mahrukh S Rizvi, et al.
Pageof 1